ClinicalTrials.gg
RecruitingNCT07123129Updated Jan 30, 2026

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

A Phase 1 interventional study of SHR-7782 Injection in Advanced Malignancy, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.

02

Conditions studied

  • Advanced Malignancy
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participate in the study voluntarily, sign the form.
  2. Subjects were able to provide primary or cancer samples.
  3. At least one ( version 1.1).
  4. 0\~1.
  5. With adequate organ functions.
  6. Expected survival time ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. With untreated or active central nervous system tumor .
  2. Imaging shows that the tumor invades large blood vessels or has unclear boundaries with blood vessels.
  3. Patients with other malignant tumors in the past or at the same time.
  4. Patients with clinical symptoms, uncontrolled, or moderate or above pleural effusion, pericardial effusion, or peritoneal effusion.
  5. Patients with a history of interstitial pneumonia or interstitial lung disease or non-infectious pneumonia requiring treatment.
  6. With poorly controlled or severe cardiovascular disease.
  7. Bleeding events of v5.0 grade ≥ 2 occurred within 1 month before the first medication.
  8. Subjects who had a serious infection within 1 month before the first medication.
  9. History of immunodeficiency.
  10. Known allergy to any component of the SHR-7782 product.
  11. According to the researcher's judgment, there are other factors that may affect the research results or cause the research to be terminated midway.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    SHR-7782 Group

    Drug: SHR-7782 Injection

Interventions

  • DrugSHR-7782 Injection

    SHR-7782 injection.

06

What researchers measure

Primary outcomes

  1. Dose Limited Toxicity (DLT)

    Time frame: Up to 21 days.

  2. Maximum Tolerated Dose (MTD)

    Time frame: Up to 6 months.

  3. Recommended Phase II Dose (RP2D)

    Time frame: Up to 21 days.

Secondary outcomes

  1. Objective Response Rate (ORR) assessed by the investigator according to RECIST 1.1 criteria

    Time frame: Up to approximately 24 months.

  2. Duration of Response (DoR) assessed by the investigator according to RECIST 1.1 criteria

    Time frame: Up to approximately 24 months.

  3. Disease Control Rate (DCR) assessed by the investigator according to RECIST 1.1 criteria

    Time frame: Up to approximately 24 months.

  4. Progression Free Survival (PFS) assessed by the investigator according to RECIST 1.1 criteria

    Time frame: Up to approximately 24 months.

  5. Overall Survival (OS)

    Time frame: Up to approximately 24 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 14, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123129
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Zhifei Lin
Contact
zhifei.lin.zl3@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion